CervoMed (CRVO) Other financing activities (2017 - 2026)

CervoMed (CRVO) posted Other financing activities of $13800.0 for Q1 2026, down 99.37% sequentially from $2.2 million in Q1 2021.

CervoMed (CRVO) Other financing activities (2017 - 2026) Analysis & Trends

CervoMed has reported Other financing activities for 6 years, with the latest figure at $13800.0 in Q1 2026.

Quarterly Other financing activities changed N/A year-over-year to $13800.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13800.0 (changed N/A YoY) and the FY2021 annual result came in at $2.2 million, up 124.11% from the prior year.
Other financing activities eased to $13800.0 in Q1 2026 per CRVO's latest filing, from $2.2 million in the prior quarter.
Over five years, Other financing activities peaked at $13800.0 in Q1 2026 and troughed at $13800.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	CervoMed	26.64 Mn	26.64 Mn	-

Download Data